Replies to post #298716 on NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

Thanks for your thoughts Doc. I was thinking more along the lines of trial milestones myself, so I was thinking topline, venue of full data presentation, and potentially filing a BLA or MAA, but you may be right that Advent manufacturing readiness could be considered a key milestone. I’m not prepared to go as far as you on the other potential milestones though, as something seemed to be holding up additional Direct trials, and now we may know why. Not sure if this has been discussed, but this language in the 10-Q looks new:

The Company’s primary focus at present is on its DCVax-L program and completion of the Phase 3 trial of DCVax-L for Glioblastoma brain cancer. Our second product, DCVax®-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed, and included treatment of a diverse range of cancers. As resources permit, the Company is working on preparations for Phase II trials of DCVax-Direct including discussions with key institutions in regard to trial design and trial preparations. The Company has stopped the DCVax-Direct contract manufacturing preparation activities at present, while the trial design activities and preparations with the trial sites continue.